The effect of Atlas-based automated segmentation (ABAS) on dose volume histogram (DVH) parameters compared to manual segmentation (MS) in loco-regional radiotherapy (RT) of early breast cancer was investigated in patients included in the Skagen Trial 1.
Introduction
Recently, an ESTRO delineation guideline-dependent atlas based automated segmentation (ABAS) tool for radiation therapy (RT) of early breast cancer using MIM Maestro software has been developed and adopted at Aarhus University Hospital, Denmark [1] [2] [3] . This ABAS tool has shown a significant reduction in segmentation time and a high agreement against a gold standard manual segmentation (MS), helping to overcome issues related to interobserver variability and workload burden of conventional manual delineation [4] . Additionally, it maintained its reproducibility and robustness in a multi-institutional clinical validation study [3] . The performance of ABAS against MS has been evaluated geometrically using Dice Similarity Coefficient (DSC), Average Hausdorrf Distance and difference in volume. However these geometric parameters have limitations [5] , and a more relevant dosimetric analysis is needed to consolidate the contribution of this tool in daily routine.
The purpose of this study was to assess if contouring variations between ABAS and MS significantly affect dose parameters. In a multi-institutional setting, the difference in dose coverage between a manually corrected ABAS and MS of CTVs of the primary (CTVp) and nodal (CTVn) volumes in patients eligible for locoregional RT of early breast cancer in the Skagen Trial 1 was investigated. 
Material and methods

Patient selection
Approved treatment plans of 40 patients were selected from a database of two previous studies investigating quality assurance and ABAS within the Skagen Trial 1 [3] . Data were obtained from 7 institutions in Denmark, Belgium and Norway. To avoid bias related to differences in target volumes or dose prescription, only patients who received treatment of all nodal levels except L1, were without boost administration or breast implants were allowed in the study. Overall, 31 out of 40 treatment plans were also included in the ABAS validation study [3] , while the others were part of the Skagen Trial 1 quality assurance protocol (Francolini et al., Quality assessment of clinical target volume delineation and dose planning in the clinically controlled randomized Skagen Trial 1, submitted to radiotherapy and Oncology).
Gold standard manual segmentation (MS)
MS of breast (CTVp_breast), chest wall (CTVp_chest wall), nodal levels except level I (CTVn) and internal mammary (CTVn_IMN) was performed by multiple observers from the participating institutions according to the ESTRO consensus guideline for target volume delineation [1, 2] . The immobilization, scanning and use of breath adaptive technique followed the institutional procedures.
Atlas based automated segmentation and manual correction ABAS was performed using four atlas libraries based on laterality and surgery, previously created on MIM Maestro TM software version 6.5 (MIM Software Inc., Cleveland, OH) [3] . ABAS was exported to the Eclipse TM treatment planning system version 11.0.31 (Varian Medical Systems Inc., Palo Alto, CA, USA) for revision and possible manual correction according to the ESTRO delineation guideline. Manual correction was performed by two research fellows (ARE and GF), blind to the MS, and approved by a breast oncologist (BVO).
Geometric comparison
Both MS and corrected ABAS (ABAS corrected ) were exported to the MIM software to calculate their spatial overlap (DSC) and volumes for each of the segmented structures. The absolute difference in volume (mL) was also calculated using the following Eq. (1):
Dosimetric comparison
For each patient, the dose plan used for treating the patient was copied to the ABAS corrected structures. DVHs were created for both MS and ABAS of CTVp, CTVn and CTVn_IMN. The DVH parameters determined for both the MS and ABAS corrected dose plans included the V90% (%) for CTVn and CTVn_IMN, the V95% (%) for CTVp either breast or chest wall and the homogeneity index (HI), calculated using the following Eq. (2) [6] :
The absolute differences in these parameters between MS and ABAS corrected were calculated using the following Eqs. (3-5): 
Results
Patients' characteristics
Twenty patients included in the study were treated at Aarhus University Hospital and the other 20 were treated at the other 6 institutions ( Table 1) .
Geometric difference
The median volume of ABAS corrected was larger than MS for CTVp_breast and CTVn. CTVp_chest wall showed a larger median volume of MS compared to the ABAS corrected . Both median MS and ABAS corrected volumes were nearly the same for CTVn_IMN. However, the difference was not significant for any of these volumes. A high spatial overlap (median DSC P0.72) was seen between MS and ABAS corrected for all compared structures. CTVp_breast showed the best agreement followed by CTVp_chest wall, CTVn and CTVn_IMN respectively ( Table 2) .
Dosimetric difference
Overall, HI comparison showed similar dose coverage for MS and ABAS corrected ; only CTVn and CTVn_IMN showed a minimal, although statistically significant, difference for this parameter. Fig. 1 shows examples of DVH for both MS and ABAS corrected structures.
Both ABAS corrected and MS showed acceptable levels of coverage on all target volumes. Differences were in favor of MS and were statistically significant only for chest wall and CTVn_IMN, with DV95% and DV90% of 2.5% and <1%, respectively ( Table 2) . Correlation between geometric and dosimetric differences
No significant correlation was found between DSC values, DVolume values or any of the DVH parameters used for CTVp_breast, CTVp_chest wall and CTVn. A statistical significant correlation between these different parameters was seen for CTVn_IMN. There was a negative correlation between DSC and DHI or DV90% (r = À0.60, p = 0.00 and À0.54, p = 0.0004, respectively) and a positive correlation between DVolume and DHI or DV90% (r = 0.40, p = 0.01 and 0.50, p = 0,001, respectively). Finally, a negative significant correlation (r = À0.44, p = 0.004) was found between DSC and DVolume for CTVn_IMN.
Discussion
The results of the current study support that ABAS with manual correction can be used safely for dose planning in loco-regional RT of early breast cancer. A DSC >0.7 indicates low inter-observer variability [7] , thus, median DSC values above 0.7 for all compared CTVs in the current study reflected high agreement between MS and ABAS corrected .
Results from the dosimetric comparison showed that dose coverage for both CTVp and CTVn, corresponding to V95% and V90%, respectively, were acceptable not only in clinical practice, but also in the context of the Skagen Trial 1. Indeed, more than 95% of both CTVp and CTVn ABAS corrected volumes were in median covered by 95% and 90% of prescribed dose, respectively. Furthermore, differences in these parameters were minimal, and only significant for CTVp_chest wall. HI comparison demonstrated overlapping DVH curves for ABAS corrected and MS (Fig. 1) .
No significant differences were found for this parameter in CTVp_breast or CTVp_chest wall reflecting a similar dose distribution for MS and ABAS corrected volumes. The median difference in HI of CTVn between ABAS corrected and MS, even if statistically significant, was only 0.01.
Thus, considering the optimal coverage levels for CTVn (V90% > 99% for both ABAS corrected and MS) this difference was not clinically relevant and under-dosage was not seen.
In a population-based study, irradiation of IMN significantly improves overall survival in node positive breast cancer patients [8] . However, in left sided patients, balance against dose to the heart and left anterior descending coronary artery is critical. In the current study, a median 96% of CTVn_IMN volumes for both ABAS corrected and MS were successfully covered by 90% of the prescribed dose, and the median differences in V90% and HI between ABAS corrected and MS for CTVn_IMN were minimal, although statistically significant.
Results of a previous work have shown low contouring variability between ABAS corrected and MS [3] . However, DSC reliability as an absolute measure of delineation variability testing has been questioned, and geometric analysis used for this purpose may have limits of performances [9] . Therefore, dosimetric comparison is recommended to evaluate the performance of automated segmentation in a more clinically relevant way [10] . Several studies have looked at the difference in DVH parameters between MS and ABAS in different tumor sites [11] [12] [13] [14] [15] [16] , and dosimetric analysis has been used to quantify the clinical effect of inter-observer variability in breast cancer RT [4, 17] . One study has reported that interobserver variability is responsible for a significant variability in dose coverage of the primary and nodal volumes among dose plans based on nine observers' contouring [4] , with a difference in V95% ranging between 10-25%. The current study has shown no significant difference in V95% between manual and automated segmentation of the breast with an inter-quartile range of about 5% for both. Target coverage was not influenced by the use of ABAS corrected or MS.
Another study has evaluated the performance of ABAS of the breast in patients treated in prone position [17] . Results have shown that a DSC >0.95 against MS has been correlated significantly to better target dose coverage. Conversely, we cannot find such correlation for the breast in the current study.
A significant correlation between variability in contouring and dosimetric differences (DSC and DV) between MS and ABAS corrected has been found for CTVn_IMN only. Therefore, a possible effect of the amount of variation on the dose distribution within this small structure will be expected and a minimal variation will ensure equal coverage. However, the dosimetric difference is clinically acceptable for both MS and ABAS corrected for CTVn_IMN in this study. Moreover, the reported dosimetric differences between MS and ABAS corrected are less than that reported in inter-observer variability studies and within the range of clinical acceptance. Therefore, the expected clinical outcome from routine use of ABAS corrected may be considered equivalent to the use of conventional MS for dose planning in loco-regional RT of breast cancer with the advantage of less time and inter-observer variability and more consistency and reproducibility for ABAS corrected compared to MS.
Impact of ABAS corrected on organs at risk was not explored in this analysis, however, it is reasonable to assume even a lower dosimetric impact on these structures.
A potential limitation of the methodology of the current study is the use of the original dose plans based on the MS rather than generating specific plans for ABAS corrected . This may theoretically bias the results. If the volume of the ABAS corrected is smaller than the MS volume, it should be covered with the designed plans. However, structures with a comparable coverage level (CTVp_breast and CTVn) between both segmentation methods have shown larger median volumes of ABAS corrected , eliminating this bias. Moreover, a better dosimetric coverage is expected if a new plan based on ABAS corrected is created. Therefore, results of the current study may represent the worst-case scenario.
Conclusions
Data from this analysis confirmed the low contouring variability between ABAS and MS.
Overall, comparison in HI and targets coverage showed that dose distribution was similar regardless of the use of ABAS or MS. Furthermore, no relationship was found between DSC and differences in coverage, reflecting that performances of ABAS did not affect dose parameters.
In the context of daily routine practice, ABAS could reduce the time in RT workflow, without meaningful dosimetric impact on treatment plan. This technique can be used in a multiinstitutional context. Thus, ABAS is a useful tool and its implementation in clinical activity should be considered.
